WO2026068951A1 - 5-méthoxy-dmt pour utilisation dans le traitement de la dépression - Google Patents

5-méthoxy-dmt pour utilisation dans le traitement de la dépression

Info

Publication number
WO2026068951A1
WO2026068951A1 PCT/GB2025/052100 GB2025052100W WO2026068951A1 WO 2026068951 A1 WO2026068951 A1 WO 2026068951A1 GB 2025052100 W GB2025052100 W GB 2025052100W WO 2026068951 A1 WO2026068951 A1 WO 2026068951A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
pharmaceutical composition
treatment
dmt
meo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/GB2025/052100
Other languages
English (en)
Inventor
Cosmo FEILDING-MELLEN
Frank Wiegand
Mathieu Julien Jean SEYNAEVE
Timothy Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckley Psytech Ltd
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Publication of WO2026068951A1 publication Critical patent/WO2026068951A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions comprenant de la 5-méthoxy-N,N-diméthyltryptamine (5-MeO-DMT) pour le traitement de la dépression chez un sujet et des méthodes d'utilisation de celles-ci. L'invention concerne en outre des méthodes d'administration de la 5-MeO-DMT à un sujet sur une période de temps suffisante pour induire une réponse clinique chez le patient.
PCT/GB2025/052100 2024-09-27 2025-09-26 5-méthoxy-dmt pour utilisation dans le traitement de la dépression Pending WO2026068951A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463700111P 2024-09-27 2024-09-27
US63/700,111 2024-09-27
US202563860436P 2025-08-08 2025-08-08
US63/860,436 2025-08-08

Publications (1)

Publication Number Publication Date
WO2026068951A1 true WO2026068951A1 (fr) 2026-04-02

Family

ID=97351489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2025/052100 Pending WO2026068951A1 (fr) 2024-09-27 2025-09-26 5-méthoxy-dmt pour utilisation dans le traitement de la dépression

Country Status (1)

Country Link
WO (1) WO2026068951A1 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160296957A1 (en) 2013-07-05 2016-10-13 Aptar France Sas Fluid or powdery product dispensing device
WO2018148605A1 (fr) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions et procédés comprenant un dérivé de psilocybine
WO2020169850A1 (fr) * 2019-02-22 2020-08-27 Gh Research Limited 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression
WO2021005308A2 (fr) 2019-07-10 2021-01-14 Aptar France Sas Dispositif de distribution nasale de poudre
WO2021250434A1 (fr) * 2020-06-12 2021-12-16 Beckley Psytech Limited Composition comprenant un sel de benzoate de 5-méthoxy-n, n-diméthyltryptamine
WO2022123128A1 (fr) 2020-12-09 2022-06-16 Aptar France Sas Dispositif de distribution de doses de poudre
WO2022171969A1 (fr) 2021-02-15 2022-08-18 Aptar France Sas Tête de distribution pour dispositif de distribution nasale d'un produit fluide ou pulvérulent
WO2022208014A1 (fr) 2021-03-29 2022-10-06 Aptar France Sas Dispositif de distribution nasale de poudre
WO2024224115A1 (fr) * 2023-04-27 2024-10-31 Beckley Psytech Limited Compositions pharmaceutiques de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)
WO2024256821A1 (fr) * 2023-06-13 2024-12-19 Beckley Psytech Limited Compositions pharmaceutiques comprenant de la 5-méthoxy-n, n-diméthyltryptamine (5-meo-dmt)
WO2025068714A1 (fr) * 2023-09-28 2025-04-03 Beckley Psytech Limited Compositions pharmaceutiques comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160296957A1 (en) 2013-07-05 2016-10-13 Aptar France Sas Fluid or powdery product dispensing device
WO2018148605A1 (fr) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions et procédés comprenant un dérivé de psilocybine
WO2020169850A1 (fr) * 2019-02-22 2020-08-27 Gh Research Limited 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression
WO2021005308A2 (fr) 2019-07-10 2021-01-14 Aptar France Sas Dispositif de distribution nasale de poudre
US20220362491A1 (en) 2019-07-10 2022-11-17 Aptar France Sas Nasal powder delivery device
WO2021250434A1 (fr) * 2020-06-12 2021-12-16 Beckley Psytech Limited Composition comprenant un sel de benzoate de 5-méthoxy-n, n-diméthyltryptamine
WO2022123128A1 (fr) 2020-12-09 2022-06-16 Aptar France Sas Dispositif de distribution de doses de poudre
WO2022171969A1 (fr) 2021-02-15 2022-08-18 Aptar France Sas Tête de distribution pour dispositif de distribution nasale d'un produit fluide ou pulvérulent
WO2022208014A1 (fr) 2021-03-29 2022-10-06 Aptar France Sas Dispositif de distribution nasale de poudre
WO2024224115A1 (fr) * 2023-04-27 2024-10-31 Beckley Psytech Limited Compositions pharmaceutiques de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)
WO2024256821A1 (fr) * 2023-06-13 2024-12-19 Beckley Psytech Limited Compositions pharmaceutiques comprenant de la 5-méthoxy-n, n-diméthyltryptamine (5-meo-dmt)
WO2025068714A1 (fr) * 2023-09-28 2025-04-03 Beckley Psytech Limited Compositions pharmaceutiques comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Salts: Properties, Selection, and Use", 2008, WILEY-VCH
"The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research", 1993, AMERICAN PSYCHIATRIC PRESS, pages: 994
AMERICAN PSYCHIATRIC ASSOCIATION: "Diagnostic and Statistical Manual of Mental Disorders", 2013, AMERICAN PSYCHIATRIC ASSOCIATION
BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
RECKWEG JOHANNES T. ET AL: "A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression", FRONTIERS IN PSYCHIATRY, vol. 14, 20 June 2023 (2023-06-20), Frontiers in psychiatrySwitzerland2020, XP093182606, ISSN: 1664-0640, Retrieved from the Internet <URL:https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1133414/full> DOI: 10.3389/fpsyt.2023.1133414 *

Similar Documents

Publication Publication Date Title
JP2021046408A (ja) 経鼻薬物製品およびその使用方法
KR20250005170A (ko) 양극성 장애의 치료를 위한 5-메톡시-n,n-디메틸트립타민
WO2025068714A1 (fr) Compositions pharmaceutiques comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)
JP2025510942A (ja) 亜酸化窒素及び５－ｈｔ２ａ受容体作動薬の組み合わせ
IL322430A (en) 5-MEO-DMT for use in the treatment of postpartum depression
JP2009519350A (ja) ヒトにおける早漏を治療するための方法
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
WO2026068951A1 (fr) 5-méthoxy-dmt pour utilisation dans le traitement de la dépression
WO2026068953A1 (fr) Méthodes et kits comprenant de la 5-meo-dmt à utiliser dans le traitement de la dépression
US20250205198A1 (en) Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
EP4701633A1 (fr) Compositions pharmaceutiques de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)
US12167995B2 (en) [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough
WO2026068950A1 (fr) Compositions pharmaceutiques de 5-meo-dmt destinées à être utilisées dans le traitement de troubles d&#39;abus de l&#39;alcool
JP2018127489A (ja) 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用
HK40106362A (en) [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough
JP2024528031A (ja) ５－ｈｔ２応答性状態を治療するための化合物及び方法
US20250221963A1 (en) 5-meo-dmt for use in the treatment of postpartum depression
HK40062321B (en) [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough
HK40062321A (en) [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough
US20250205200A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
OA20600A (en) [((1R,2S,5R)-2-Isopropyl-5-Methyl-Cyclohexanecarbonyl)-Amino]-Acetic acid Isopropyl ester for treatment of chronic cough.
EA046106B1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТА mGluR5 ДЛЯ ЛЕЧЕНИЯ ТОЛЕРАНТНОСТИ К ОПИОИДНЫМ АНАЛЬГЕТИКАМ
HK1197916B (en) Use of beta-adrenergic inverse agonists for smoking cessation
HK1197916A (en) Use of beta-adrenergic inverse agonists for smoking cessation